for Journals by Title or ISSN
for Articles by Keywords
Followed Journals
Journal you Follow: 0
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Jurnals are published.
Already have an account? Sign In to see the journals you follow.
Journal Cover   PharmAsia News
  [0 followers]  Follow
   Full-text available via subscription Subscription journal
   ISSN (Print) 1875-7774
   Published by Informa plc Homepage  [16 journals]
  • Biopharma Execs Go Face-To-Face With Obama Over TPP
    • Abstract: President Barack Obama heard firsthand from a half dozen or so biopharmaceutical executives during an Oct. 8 White House face-to-face meeting about the industry's disappointment in the administration for agreeing to a minimum of five years of exclusivity protection for innovator biologics against biosimilars in the final TPP trade deal, rather than the 12 years required in the US by law.
      PubDate: Fri, 09 Oct 2015 01:25:00 -040
  • Chinese Scientist’s Nobel Should Be Wakeup Call, Insiders Say
    • Abstract: For a nation where millions of scientific students graduate each year but there have been no Nobel Prize winners in the sciences until this week, China gave surprisingly little recognition to its first Nobel Laureate in the area during her decades-long quest to develop a traditional herbal medicine into a global malaria treatment.
      PubDate: Thu, 08 Oct 2015 22:05:01 -040
  • EFPIA Highlights Europe ‘Lessons’ As Japan Ponders Policies
    • Abstract: EFPIA remains cautious over moves in Japan towards a formal health technology assessment system and possible changes to the reimbursement pricing system, calling again for the maintenance of an environment conducive to pharma innovation and pointing to lessons from its experience in Europe.
      PubDate: Thu, 08 Oct 2015 21:10:00 -040
  • Permanent Indian Bar Against Glenmark’s Sitagliptin Copies
    • Abstract: An Indian court has permanently enjoined Glenmark from making and selling its generic version of Merck’s diabetes therapies Januvia and Janumet after the Indian firm was found to have infringed the sitagliptin patent.
      PubDate: Thu, 08 Oct 2015 02:15:02 -040
  • Blockbuster Patent Expiries Sparking Korean Generic War
    • Abstract: With patents for a series of global blockbuster drugs expiring this year, South Korean pharma firms are fiercely competing to grab bigger pieces of the domestic generic market. Amid an ongoing patent invalidation suit concerning BMS’s Baraclude, Dong-A ST has been banned from producing and selling its generic version until the patent expires, while the Korean pharma association has warned its members against illegal rebates amid intensifying generic competition.
      PubDate: Wed, 07 Oct 2015 23:55:01 -040
  • INTERVIEW: Business Is Personal For Avita CEO Kelliher
    • Abstract: As a former war correspondent on the battlefields of the Balkans, Afghanistan and Iraq, new Avita Medical chief executive Adam Kelliher can claim to have an up-close understanding of the types of injuries that his regenerative medicine company’s lead product is designed to heal.
      PubDate: Wed, 07 Oct 2015 21:20:01 -040
  • Asia, Neglected Diseases Score Big In Nobel Prize Win
    • Abstract: Health campaigners and organizations working in the area of drugs for neglected diseases have hailed the Nobel Prize awarded to three researchers in the field, but the move also highlights shortcomings and research gaps.
      PubDate: Wed, 07 Oct 2015 02:35:01 -040
  • Asia On The Move: Pfizer Exec To Head BeiGene’s Manufacturing Ops
    • Abstract: The coming of autumn has brought a flurry of personnel changes in Asia, with China oncology startup BeiGene continuing its expansion by hiring away talent from Pfizer and WuXi Apptec, while two genome testing firms have set up R&D subsidiaries in China, further heating up the competition in a red hot area. Change has also taken place at the top of the US industry association PhRMA.
      PubDate: Tue, 06 Oct 2015 21:10:01 -040
  • Australia Toughens Code On Pharma’s Financial Ties To Doctors
    • Abstract: From the beginning of this month, Australian pharmaceutical companies will be required to collect information about any payments they make to health care professionals for consulting services and any financial support they provide for educational purposes, including airfares, accommodation and conference registration fees.
      PubDate: Tue, 06 Oct 2015 20:55:00 -040
  • Evogliptin Set For First Launch, In Crowded Korean Market
    • Abstract: Dong-A ST's new type 2 diabetes therapy Suganon (evogliptin) has been approved in South Korea where it is set to compete with a number of already marketed DPP-4 inhibitors in an increasingly crowded sector. The domestic approval follows global licensing out deals for the drug in the past few years in other markets including China, India, Brazil and Russia.
      PubDate: Tue, 06 Oct 2015 02:00:00 -040
  • TPP: ‘Missed Opportunity’ Or ‘Unprecedented
    • Abstract: Some form of consensus among the 12 countries taking part in the Trans-Pacific Partnership free trade talks may have been reached on the highly charged issue of biologics' exclusivity, but there is still a lack of transparency on the details while the basic deal seems to be satisfying no one outside the closed circle of negotiators.
      PubDate: Tue, 06 Oct 2015 01:35:00 -040
  • Did Biopharma Really Lose In TPP Trade Deal'
    • Abstract: After more than six years of intense efforts to lobby a group of Asia-Pacific trade ministers – a pact that eventually involved representatives from 12 nations – the innovator biopharmaceutical industry failed to get what it most wanted in the Trans-Pacific Partnership (TPP): 12 years of data exclusivity protection for biologics against biosimilars.
      PubDate: Mon, 05 Oct 2015 20:25:02 -040
  • Turkey Preps Device Inventory Under Industry Booster Plans
    • Abstract: The Turkish Medicines and Medical Devices Agency is working on a project to prepare a production inventory of medical devices that it hopes will aid investors’ decisions, as part of several important enacted and planned policy moves this year to improve quality and technology in the growing industry.
      PubDate: Mon, 05 Oct 2015 04:10:02 -040
  • Emerging Physician Groups Reshaping China Healthcare Landscape
    • Abstract: From simply selling products to providing broad business solutions, medical device and service companies in China are now rushing to satisfy the needs of a rising tide of increasingly influential independent physician practice groups in China. Cloud-based diagnostic centers and specialist training are just some of the first steps, says one Chinese healthcare executive.
      PubDate: Mon, 05 Oct 2015 00:50:00 -040
  • Novel Parkinson’s Therapy Moves Ahead Through Korea Deal
    • Abstract: South Korean researchers have taken a step forward in developing a disease-modifying treatment for Parkinson's disease. Kainos Medicine has licensed in an innovative candidate for the now incurable disease, KR-33493, which is set for clinical trials in the country and is expected to be a first-in-class drug that can curb dopaminergic neuronal cell death.
      PubDate: Sun, 04 Oct 2015 22:05:00 -040
  • India’s API Build-Up Plan To Bridle The Dragon
    • Abstract: An Indian expert committee has recommended a raft of measures to revive and promote the production of active pharmaceutical ingredients (APIs) in the country, including the "judicious and liberal" use of anti-dumping duties and safeguards, with an eye on the country's huge reliance on Chinese imports.
      PubDate: Sun, 04 Oct 2015 20:35:00 -040
  • Genovate Aims For Global Insulin Position Under $1bn Project
    • Abstract: Genovate has begun construction of its first manufacturing facility for insulins as part of a total investment of $1bn and with the ambition to become China’s first, and the world's fourth largest, manufacturer of insulin using efficient and ecologically friendly production technology.
      PubDate: Fri, 02 Oct 2015 01:40:00 -040
  • Compromises Set To Unlock TPP Endgame'
    • Abstract: What is expected to be the final round of ministerial talks to seal the long-planned Trans-Pacific Partnership free trade agreement has begun in Atlanta, but external opposition to expected drug and particularly biologics intellectual property measures remains firm.
      PubDate: Thu, 01 Oct 2015 22:25:02 -040
  • Govt Support Bolsters Pharmicell’s Stem Cell Therapy Plans
    • Abstract: Pharmicell is to kick off the development of a stem cell-based therapy for chronic kidney disease and a gene therapy for liver cancer with support from the South Korean government, which is nurturing the development of both sectors as part of a national strategic plan.
      PubDate: Thu, 01 Oct 2015 20:55:00 -040
  • Malaysia Aiming To Reduce Info For Device GDP Certificates
    • Abstract: Malaysia's Medical Device Authority is inviting feedback on its proposal to reduce the amount of information that conformity assessment bodies need to include in the good distribution practice certificates they issue to various entities.
      PubDate: Thu, 01 Oct 2015 02:10:01 -040
  • Long Hot Summer For Vaccines Policies In Turkey
    • Abstract: Turkey has a growing vaccines market and a strong national vaccination program. But the sector has come under fire from different directions this summer and the government and academic circles have had to defend vaccination policies and practices in public.
      PubDate: Thu, 01 Oct 2015 01:05:00 -040
  • Law Change Would Help Kolon As It Progresses Pipeline
    • Abstract: Kolon life Science expects South Korea’s government to ease gene therapy rules to help the company launch its osteoarthritis drug in the domestic market, and is looking to complete licensing talks with potential global partners before the product's launch, the venture said at a recent investors’ meeting.
      PubDate: Wed, 30 Sep 2015 22:25:02 -040
  • Astellas, Chromocell In Pain Pact Worth $515m-plus
    • Abstract: Astellas will pay Chromocell $15m up front and could spend more than $500m on milestone fees under a license and collaboration agreement for Nav1.7 antagonists, including lead drug candidate CC8464 and backup compounds, for the treatment of neuropathic pain and other conditions.
      PubDate: Wed, 30 Sep 2015 20:40:01 -040
  • China’s New Stem Cell Guidelines To Shake Up Industry'
    • Abstract: China is releasing additional regulations governing clinical trials with stem cell therapies following its first new administrative measures this year, in order to better regulate the market. The changes are expected to result in a reshuffle of the industry and the flushing out of up to 80% of companies currently involved in the field, with the focus of the supply chain set to shift to the middle ground.
      PubDate: Wed, 30 Sep 2015 02:30:01 -040
  • Japan First To Approve Omarigliptin, Lusutrombopag
    • Abstract: The latest batch of product approvals in Japan includes the first regulatory clearances worldwide for new molecules from Merck and Shionogi, in a further sign that the country's "drug lag" is a thing of the past.
      PubDate: Wed, 30 Sep 2015 01:50:00 -040
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2015